<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of supraventricular tachycardia (SVT) in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of supraventricular tachycardia (SVT) in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of supraventricular tachycardia (SVT) in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anne M Dubin, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John K Triedman, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Carrie Armsby, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 29, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Supraventricular tachycardia (SVT) can be defined as an abnormally rapid heart rhythm originating above the ventricles, often (but not always) with a narrow QRS complex; it conventionally excludes atrial flutter and atrial fibrillation [<a href="#rid1">1</a>].</p><p>The management of SVT in children will be reviewed here. Two major issues will be addressed: acute management to terminate the arrhythmia and chronic therapy to prevent recurrence. The clinical features of the different types of SVT are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5783.html" rel="external">"Clinical features and diagnosis of supraventricular tachycardia (SVT) in children"</a>.)</p><p>Management of patients with preexcitation on electrocardiogram (Wolff-Parkinson-White pattern)  (<a class="graphic graphic_waveform graphicRef75578" href="/z/d/graphic/75578.html" rel="external">waveform 1</a>) but without a symptomatic arrhythmia is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/962.html" rel="external">"Wolff-Parkinson-White syndrome: Anatomy, epidemiology, clinical manifestations, and diagnosis", section on 'Risk stratification of asymptomatic patients with WPW pattern'</a> and  <a class="medical medical_review" href="/z/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Asymptomatic patients'</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">ACUTE MANAGEMENT</span><span class="headingEndMark"> — </span>Acute management of the child who presents with SVT can be a challenge because the exact mechanism of the tachycardia often is unknown. The treatment strategy depends upon the patient's presentation and clinical status (hemodynamically stable or unstable). The approach consists of initiating therapy while continuing to assess the patient's condition  (<a class="graphic graphic_table graphicRef53559" href="/z/d/graphic/53559.html" rel="external">table 1</a>). The following discussion is generally in agreement with the 2010 Pediatrics Advanced Life Support guidelines developed by the American Heart Association (AHA) and the International Liaison Committee on Resuscitation (ILCOR)  (<a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">algorithm 1</a>) [<a href="#rid2">2</a>]. The AHA/ILCOR guidelines were updated in 2015; however, the guidelines for tachyarrhythmias remained unchanged [<a href="#rid3">3</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Hemodynamic assessment and monitoring</span><span class="headingEndMark"> — </span>An infant or child who presents with a tachyarrhythmia should have an immediate hemodynamic assessment and an electrocardiogram (ECG) performed  (<a class="graphic graphic_table graphicRef53559" href="/z/d/graphic/53559.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">algorithm 1</a>). A 15-lead ECG is generally preferred. This includes the 12 standard leads plus leads V3R and V4R (right-sided leads analogous to V3 and V4 on the left) and V7 (left posterior axillary line at V4 level). Continuous ECG monitoring during therapeutic maneuvers provides insight into the cause of tachycardia and helps in the planning of chronic therapy.</p><p>The most important initial clinical determination to make in children presenting with a tachyarrhythmia is whether there are signs of hemodynamic instability, including hypotension, heart failure, poor perfusion, shock, or decreased level of consciousness. Unstable patients require immediate intervention to terminate the rhythm.</p><p>Affected children can be asymptomatic except for fussiness or palpitations or may be unconscious with signs of cardiovascular collapse. The acute management depends on whether the patient is hemodynamically stable or not  (<a class="graphic graphic_table graphicRef53559" href="/z/d/graphic/53559.html" rel="external">table 1</a>).</p><p>A broader discussion of the approach to assessing children with tachycardia is presented separately. (See  <a class="medical medical_review" href="/z/d/html/6435.html" rel="external">"Approach to the child with tachycardia", section on 'Algorithmic approach'</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">Unstable patients</span><span class="headingEndMark"> — </span>Unstable patients with hemodynamic compromise (eg. depressed consciousness, poor perfusion, hypotension, or other signs of shock or severe heart failure) require immediate termination of the tachyarrhythmia  (<a class="graphic graphic_table graphicRef53559" href="/z/d/graphic/53559.html" rel="external">table 1</a>). Cardioversion is the definitive intervention.</p><p class="headingAnchor" id="H3630486366"><span class="h3">Interventions while preparing to cardiovert</span><span class="headingEndMark"> — </span>While preparing to cardiovert, supplemental oxygen and other respiratory support should be provided as needed. <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> may be given while preparing to cardiovert if the drug is readily available and the child has intravenous (IV) access. Similarly, vagal maneuvers can be attempted while preparing for cardioversion or drug therapy, but cardioversion should not be delayed to administer vagal maneuvers. (See <a class="local">'First-line therapy (adenosine)'</a> below and <a class="local">'Vagal maneuvers'</a> below.)</p><p>In general, the child should be given adequate analgesia and sedation before cardioversion [<a href="#rid4">4,5</a>]. Rarely, a child is too critically ill to delay the procedure for administration of sedation. The approach to procedural sedation in children is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6330.html" rel="external">"Procedural sedation in children: Approach"</a>.)</p><p class="headingAnchor" id="H5"><span class="h3">Cardioversion</span><span class="headingEndMark"> — </span>Cardioversion is the definitive intervention to terminate SVT in children who are hemodynamically unstable. Direct current cardioversion is performed using an energy dose of 0.5 to 1 J/kg, which can be increased to 2 J/kg if the lower dose is ineffective [<a href="#rid2">2,6</a>]. A narrow complex tachycardia should be converted in <strong>synchronous mode</strong>, in which a shock is not delivered during the vulnerable repolarization period; this will avoid possible precipitation of ventricular fibrillation. Additional details of the procedure, including electrode size and choice of handheld paddles versus self-adhesive pads, are provided separately. (See  <a class="medical medical_review" href="/z/d/html/6311.html" rel="external">"Technique of defibrillation and cardioversion in children (including automated external defibrillation)", section on 'Procedure'</a>.)</p><p>Synchronous direct-current cardioversion is highly effective for all types of SVT and restores sinus rhythm in &gt;95 percent of cases when properly administered [<a href="#rid7">7-10</a>]. (See  <a class="medical medical_review" href="/z/d/html/983.html" rel="external">"Cardioversion for specific arrhythmias", section on 'Efficacy'</a>.)</p><p class="headingAnchor" id="H1339194115"><span class="h2">Stable patients</span><span class="headingEndMark"> — </span>In patients who are hemodynamically stable, additional time can be given to evaluate the rhythm and to attempt vagal maneuvers to terminate the tachyarrhythmia. If the rhythm does not terminate with vagal maneuvers, <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> is given.</p><p class="headingAnchor" id="H6"><span class="h3">Diagnostic evaluation</span><span class="headingEndMark"> — </span>The following findings support the presence of an SVT [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Abrupt onset of tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Heart rate &gt;220 beats/min in infants and &gt;180 beats/min in children</p><p class="bulletIndent1"><span class="glyph">●</span>P waves absent or abnormal</p><p class="bulletIndent1"><span class="glyph">●</span>Heart rate does not vary with activity</p><p></p><p>The vast majority of SVT episodes in children with structurally normal hearts involve classic atrioventricular (AV) reentry. The potential mechanisms include:</p><p class="bulletIndent1"><span class="glyph">●</span>AV reentrant tachycardia (AVRT) due to either a manifest or concealed accessory pathway (see  <a class="medical medical_review" href="/z/d/html/976.html" rel="external">"Atrioventricular reentrant tachycardia (AVRT) associated with an accessory pathway"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>AV nodal reentrant tachycardia (AVNRT) (see  <a class="medical medical_review" href="/z/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia"</a>)</p><p></p><p>The discussion in this topic focuses primarily on these common mechanisms. Rare pediatric cases may involve other mechanisms such as atrial ectopic tachycardia or atrial flutter. The diagnostic evaluation of AVRT, AVNRT, and other types of SVT is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5783.html" rel="external">"Clinical features and diagnosis of supraventricular tachycardia (SVT) in children", section on 'Diagnosis'</a> and  <a class="medical medical_review" href="/z/d/html/14407.html" rel="external">"Atrial tachyarrhythmias in children"</a>.)</p><p class="headingAnchor" id="H7"><span class="h3">Vagal maneuvers</span><span class="headingEndMark"> — </span>In children who have mild or no symptoms, vagal maneuvers should be attempted while supplies and personnel are assembled to proceed to medical therapy, if needed. These maneuvers should be performed while the ECG is continuously monitored. The ECG pattern seen during termination of the tachycardia can help determine its mechanism.</p><p>In infants, the vagal maneuver most commonly used is application of a bag filled with ice and cold water over the face for 15 to 30 seconds. This elicits the diving reflex, frequently interrupting the arrhythmia [<a href="#rid11">11</a>]. Another method that may be successful in infants is rectal stimulation using a thermometer.</p><p>In older children, vagal maneuvers include bearing down (Valsalva maneuver), blowing into an occluded straw, or assuming a head-down position for 15 to 20 seconds.</p><p>Carotid massage and orbital pressure should <strong>not</strong> be performed in children.</p><p>Vagal maneuvers are successful in 60 to 90 percent of cases [<a href="#rid12">12-15</a>]. (See  <a class="medical medical_review" href="/z/d/html/1034.html" rel="external">"Vagal maneuvers"</a>.)</p><p class="headingAnchor" id="H8"><span class="h3">Supraventricular tachycardia refractory to vagal maneuvers</span><span class="headingEndMark"> — </span>If the vagal maneuver does not convert SVT that is hemodynamically stable to normal rhythm, an IV catheter should be placed for the administration of antiarrhythmic drugs. <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> is the preferred drug for acute management of SVT because it successfully converts approximately 75 to 95 percent of cases and, while side effects are common, they are generally mild and short lived.</p><p class="headingAnchor" id="H9"><span class="h4">First-line therapy (adenosine)</span><span class="headingEndMark"> — </span><a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> is considered the drug of choice for acute medical conversion of SVT in children  (<a class="graphic graphic_table graphicRef53559" href="/z/d/graphic/53559.html" rel="external">table 1</a> and <a class="graphic graphic_waveform graphicRef51178" href="/z/d/graphic/51178.html" rel="external">waveform 2</a> and <a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">algorithm 1</a>) [<a href="#rid2">2,16-19</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – We suggest the following procedure for <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> administration:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The usual initial dose is 0.1 mg/kg IV (maximum dose 6 mg).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Adenosine should administered by rapid IV injection at a site as close to the central circulation as possible, followed immediately by a 5 mL normal <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> flush. The use of two syringes (one with <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> and the other with normal saline flush) connected to a three-way stopcock is a useful way of ensuring rapid and effective drug delivery.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The patient should be supine and should have continuous ECG and blood pressure monitoring.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If no response is seen within two minutes, the dose should be doubled (ie, 0.2 mg/kg IV, maximum dose 12 mg).</p><p></p><p class="bulletIndent1">An alternative regimen consists of an initial bolus of 0.05 mg/kg; if no response is seen within two minutes, the dose is increased by 0.05 mg/kg increments every two minutes until termination of the arrhythmia or a maximum dose of 0.25 to 0.35 mg/kg or 12 mg is given.</p><p></p><p class="bulletIndent1">The IV injection procedure described above facilitates rapid delivery to the heart, which is necessary because the drug is quickly metabolized to an inactive form by an enzyme on the red cell surface. Higher doses are typically necessary when given peripherally compared with centrally [<a href="#rid2">2</a>]. In one study, the average effective dose was approximately 0.13 mg/kg (range 0.05 to 0.25 mg/kg) [<a href="#rid20">20</a>]. The wide range likely reflects differences in how the drug was given.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Contraindications and cautions</strong> – Cautions with <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> use include the following:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> is contraindicated in patients with preexisting second- or third-degree heart block or sinus node disease [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients with Wolff-Parkinson-White (WPW) syndrome, <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> can precipitate atrial fibrillation that can degenerate into ventricular fibrillation. This is an extremely rare event and does <strong>not</strong> imply that adenosine should be avoided in patients with WPW. To the contrary, adenosine is considered the first-line treatment for SVT in patients with WPW. However, clinicians should be aware of this potential and emergency resuscitation equipment should be available [<a href="#rid22">22</a>]. (See  <a class="medical medical_review" href="/z/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Orthodromic AVRT'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with asthma may experience acute bronchospasm with <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> administration [<a href="#rid23">23,24</a>], though this is uncommon in children without an asthma history [<a href="#rid25">25</a>]. Underlying asthma is not a contraindication to using adenosine, but clinicians should be aware of the potential for bronchospasm. The mechanism for adenosine-induced bronchospasm is uncertain but may be related to stimulation or enhancement of mast cell-derived mediators [<a href="#rid23">23</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In patients who have undergone heart transplantation, <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> administration can cause prolonged AV block. This is a consequence of parasympathetic denervation, which increases the sensitivity of the sinus and AV node receptors [<a href="#rid26">26</a>]. Thus, when adenosine is used to treat SVT in patients who have undergone heart transplant, we suggest starting with a low dose (0.025 mg/kg, maximum dose 1.5 mg) with gradual dose escalation. This dosing regimen appears to be safe in heart transplant patients [<a href="#rid27">27</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Side effects</strong> – Side effects, including flushing, nausea, vomiting, vague feeling of discomfort, chest pain, and dyspnea, are common with <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> but usually resolve rapidly [<a href="#rid18">18,20,25,28,29</a>]. Serious side effects, such as arrhythmias, are rare [<a href="#rid25">25</a>]. Adenosine can precipitate atrial fibrillation, although this usually terminates spontaneously [<a href="#rid20">20,22</a>]. IV adenosine should be administered in a setting where appropriate monitoring and resuscitation equipment (eg, oxygen, defibrillator) are readily available and where adverse events can be managed.</p><p></p><p class="bulletIndent1">In a multicenter report of 98 episodes of presumptive SVT episodes treated with IV <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> in the emergency department setting, adverse effects were observed in 22 percent [<a href="#rid25">25</a>]. Patients who received multiple doses and/or doses &gt;0.2 mg/kg were more likely to experience adverse effects compared with those who received a single-dose and total dose ≤0.2 mg/kg. The most common side effects were nausea/vomiting (10 percent), chest discomfort (6 percent), flushing (4 percent), headache (3 percent), dyspnea (2 percent), and bradycardia (2 percent). No patient experienced a hemodynamically significant arrhythmia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy and mechanism of action</strong> – The efficacy of <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> for acute treatment of SVT in children is supported by retrospective case series [<a href="#rid8">8,18,20,25,30-32</a>]. In the available reports, adenosine terminated 80 to 95 percent of episodes of AVRT, which accounts for almost three-quarters of episodes of SVT [<a href="#rid31">31,32</a>] and approximately 75 percent of episodes due to other causes of SVT [<a href="#rid18">18,20,25</a>]. Early recurrence of the SVT after termination occurs in 25 to 30 percent of cases [<a href="#rid18">18,20</a>].</p><p></p><p class="bulletIndent1">Though clinical trials are lacking in children, trials in adults have demonstrated that <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a>'s efficacy in terminating SVT is comparable with that of <a class="drug drug_pediatric" data-topicid="12879" href="/z/d/drug information/12879.html" rel="external">verapamil</a> [<a href="#rid33">33</a>]. In children, adenosine is preferred over verapamil because of its very short duration of action and because there are a number of settings in which verapamil should not be used (eg, infants &lt;12 months old), as discussed below. (See <a class="local">'Supraventricular tachycardia refractory to adenosine'</a> below.)</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> acts by interacting with A1 receptors on the surface of cardiac cells; the resulting effects include slowing of the sinus rate and an increase in the AV nodal conduction delay [<a href="#rid30">30</a>]. This interrupts the reentrant circuit of tachycardias that require the AV node for reentry.</p><p></p><p class="bulletIndent1">Vagal stimulation caused by <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> is brief and self-limited. The onset of effect is almost immediate: The half-life is less than 5 to 10 seconds. The effects of adenosine are diminished by methylxanthines such as <a class="drug drug_pediatric" data-topicid="13360" href="/z/d/drug information/13360.html" rel="external">caffeine</a> or <a class="drug drug_pediatric" data-topicid="12831" href="/z/d/drug information/12831.html" rel="external">theophylline</a>.</p><p></p><p class="headingAnchor" id="H4279881594"><span class="h4">Supraventricular tachycardia refractory to adenosine</span><span class="headingEndMark"> — </span>If <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> fails to convert SVT to sinus rhythm, there are three potential explanations:</p><p class="bulletIndent1"><span class="glyph">●</span>The medication may not have been administered rapidly enough or close enough to the central circulation. In this case, the ECG recording during <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> administration typically shows no interruption in the rhythm. Optimizing the administration technique in subsequent doses, as described above, may result in successful termination of the rhythm. (See <a class="local">'First-line therapy (adenosine)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The tachyarrhythmia may be due to an alternate mechanism such as atrial ectopic tachycardia (AET) or atrial flutter. The ECG recording during <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> administration can be of diagnostic utility in these cases  (<a class="graphic graphic_waveform graphicRef72312" href="/z/d/graphic/72312.html" rel="external">waveform 3</a>). Management of AET and atrial flutter are beyond the scope of this topic review. Consultation with a pediatric cardiologist is advised. (See  <a class="medical medical_review" href="/z/d/html/14407.html" rel="external">"Atrial tachyarrhythmias in children", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The SVT may be truly refractory to <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a>.</p><p></p><p>For SVT that is refractory to <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a>, choices for IV antiarrhythmic therapy include <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a> and <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a>. <a class="drug drug_pediatric" data-topicid="12879" href="/z/d/drug information/12879.html" rel="external">Verapamil</a> is another option in older children; however, its use is limited. These drugs have potential for serious adverse effects and therefore consultation with a pediatric cardiologist is advised. Beta blocker therapy is an alternative to IV antiarrhythmic therapy if the SVT appears to be well tolerated (ie, hemodynamically stable and no symptoms) and the patient is in a closely monitored setting. <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">Digoxin</a> is not usually used, because of the delay in achieving therapeutic levels and the narrow therapeutic margin with the risk of serious toxicity [<a href="#rid6">6</a>]. In addition, digoxin should <strong>not</strong> be given if WPW syndrome is suspected, since it may potentiate accessory pathway conduction.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Procainamide</strong> – SVT that is refractory to <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> may respond to IV <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a>. In neonates, a loading dose of 7 to 10 mg/kg is given IV over 30 to 45 minutes. In infants and older children, the loading dose is 10 to 15 mg/kg. This is followed by a continuous IV infusion starting at 20 mcg/kg per minute. Plasma levels should be measured four hours after completion of the loading dose, during the maintenance infusion.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">Procainamide</a> has potential for serious adverse effects, and, therefore, consultation with a pediatric cardiologist is advised. Negative inotropic effects may occur following the administration of procainamide. In addition, procainamide can prolong the QT interval and therefore should not be given with other drugs that prolong QT. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">Procainamide</a> is a class IA antiarrhythmic drug that acts primarily by inhibiting phase 0 (sodium-dependent) depolarization and slows atrial conduction. Unlike <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> and <a class="drug drug_pediatric" data-topicid="12879" href="/z/d/drug information/12879.html" rel="external">verapamil</a>, procainamide acts by slowing conduction within the myocardium itself, rather than by blocking reentry at the AV node. As a result, procainamide may be used safely in patients with WPW syndrome without the risk of provoking accessory pathway conduction.</p><p></p><p class="bulletIndent1">In a retrospective study of 40 episodes of acute refractory SVT managed at a single institution, the success rate with <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a> appeared to be superior to that of <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> (71 versus 34 percent) [<a href="#rid34">34</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">Procainamide</a>'s use in pediatric resuscitation is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6386.html" rel="external">"Primary drugs in pediatric resuscitation", section on 'Procainamide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Amiodarone</strong> – <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a> is generally reserved for SVT that is refractory to other agents (<a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a>, <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a>) [<a href="#rid35">35</a>]. Like procainamide, it can be used safely in patients with WPW syndrome so long as the SVT has a narrow and regular QRS complex. Amiodarone is considered contraindicated in preexcited atrial fibrillation, which has an irregular and wide QRS complex. (See  <a class="medical medical_review" href="/z/d/html/962.html" rel="external">"Wolff-Parkinson-White syndrome: Anatomy, epidemiology, clinical manifestations, and diagnosis", section on 'Atrial fibrillation'</a>.)</p><p></p><p class="bulletIndent1">Different dosing regimens have been described. We typically use a bolus infusion of 5 mg/kg IV over 20 to 60 minutes. If there is no response, the bolus dose is repeated up to a total of 15 mg/kg. If the patient responds, this is followed by a continuous IV infusion of 10 to 15 mg/kg per day.</p><p></p><p class="bulletIndent1">Adverse events are common with IV <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> use in children and may be severe. Consultation with a pediatric cardiologist is advised. Adverse effects such as nausea and vomiting are common. Severe adverse effects can also occur, including hypotension, bradycardia, AV block, and cardiovascular collapse [<a href="#rid35">35-38</a>]. ECG and blood pressure monitoring should be performed during administration of IV amiodarone. Both amiodarone and <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a> can prolong the QT interval, and they should not be given together. (See  <a class="medical medical_review" href="/z/d/html/1043.html" rel="external">"Acquired long QT syndrome: Definitions, pathophysiology, and causes"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a> is a class III antiarrhythmic agent. The IV preparation prolongs the refractory period of the AV node and, to a lesser degree, the duration of the action potential and the refractory period of both atrial and ventricular myocardium [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1">The efficacy of <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> in the acute treatment of SVT in children is supported by several small case series and one prospective dose-finding clinical trial [<a href="#rid35">35,37,40,41</a>]. The success rates in these reports range from 47 to 87 percent. Factors that likely influenced the success rates in these studies include the dose of amiodarone used, age of the child (success was less likely in infants &lt;12 months [<a href="#rid41">41</a>]), and type of tachyarrhythmia studied (response rates were generally higher in studies limited to SVT compared with studies that included other tachyarrhythmias). In the one prospective clinical trial, which involved 61 children (mean age 4.1 years) with incessant tachyarrhythmias (SVT accounted for approximately one-half), the response time was fastest and the response rate was greatest in patients who received high-dose amiodarone (ie, 10 mg/kg loading dose followed by 10 mg/kg per day continuous infusion) [<a href="#rid37">37</a>]. However, dose-related adverse events were common, occurring in 87 percent of patients, including two deaths that were possibly drug-related. For this reason, IV amiodarone should be used with caution in patients who are otherwise hemodynamically stable and it should only be administered in an acute care setting where hypotension and bradycardia can be promptly treated.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a>'s use in pediatric resuscitation is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/6386.html" rel="external">"Primary drugs in pediatric resuscitation", section on 'Amiodarone'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Verapamil</strong> – <a class="drug drug_pediatric" data-topicid="12879" href="/z/d/drug information/12879.html" rel="external">Verapamil</a> is an effective acute therapy to slow AV nodal conduction and terminate SVT in children older than one year. Verapamil is administered as an IV infusion in a dose of 0.1 to 0.3 mg/kg with a maximum dose of 10 mg.</p><p></p><p class="bulletIndent1"><a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> is preferred over <a class="drug drug_pediatric" data-topicid="12879" href="/z/d/drug information/12879.html" rel="external">verapamil</a> for first-line therapy because of its very short duration of action. In addition, there are a number of settings in which verapamil should <strong>not</strong> be used:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In infants &lt;1 year old because it may cause apnea, hypotension, bradycardia, and cardiovascular collapse [<a href="#rid42">42,43</a>]. The mechanism of this complication may be a poorly developed sarcoplasmic reticulum in infants, so that myocardial contractility depends solely on calcium channels.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children with heart failure [<a href="#rid6">6,42</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children with known or suspected WPW syndrome since it may potentiate conduction down an antegrade conducting pathway and provoke ventricular fibrillation [<a href="#rid6">6</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In children with a wide QRS complex tachycardia since it can provoke severe hemodynamic deterioration in those who have ventricular tachycardia rather than an SVT [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers</strong> – In patients with SVT that does not initially respond to <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> and in whom the rhythm appears to be well tolerated (ie, hemodynamically stable and no symptoms), beta blocker therapy with IV <a class="drug drug_pediatric" data-topicid="13279" href="/z/d/drug information/13279.html" rel="external">esmolol</a> (loading dose 100 to 500 mcg/kg over one minute, followed by an infusion of 25 to 100 mcg/kg/min) or oral <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a> (0.5 mg/kg as a single dose) may be used as alternate or ancillary pharmacologic therapy, provided that the patient continues to be closely monitored until sinus rhythm is restored. If the patient does not self-convert after an hour, repeat dosing with adenosine can be attempted. (See <a class="local">'First-line therapy (adenosine)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Digoxin</strong> – <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">Digoxin</a> is not usually used for acute SVT treatment, because of the delay in achieving therapeutic levels and the narrow therapeutic margin with the risk of serious toxicity [<a href="#rid6">6</a>]. In addition, digoxin should <strong>not</strong> be given if WPW syndrome is suspected, since it may potentiate accessory pathway conduction.</p><p></p><p class="headingAnchor" id="H13"><span class="h4">Transesophageal pacing</span><span class="headingEndMark"> — </span>Transesophageal pacing may be a useful adjunct to therapy for SVT in a child; however, it requires the expertise of cardiologists who are very familiar with the technique [<a href="#rid6">6</a>]. The technique involves electrical atrial stimulation until the tachyarrhythmia resolves or until other therapies can be initiated [<a href="#rid6">6,45</a>]. It can be used to determine the mechanism of and to terminate the tachycardia. This is particularly valuable in the management of the infant who is refractory to pharmacologic therapy or with incessant recurrence of SVT, in that it can be repeatedly used without additional exposure to the potential adverse effects of pharmacologic cardioversions. In one report involving 63 patients (mostly adults), transesophageal pacing successfully terminated SVT in all but one [<a href="#rid45">45</a>]. However, transesophageal pacing requires specialized personnel and equipment. Sedation of the child may be necessary because the procedure can be uncomfortable.</p><p class="headingAnchor" id="H4185606911"><span class="h1">EVALUATION AFTER THE ACUTE EPISODE</span><span class="headingEndMark"> — </span>After the acute episode is terminated, an electrocardiogram (ECG) and echocardiogram should be performed. The ECG is obtained to look for evidence of Wolff-Parkinson-White (WPW) syndrome (the presence of a wide QRS complex with a "delta wave")  (<a class="graphic graphic_waveform graphicRef75578" href="/z/d/graphic/75578.html" rel="external">waveform 1</a>). (See  <a class="medical medical_review" href="/z/d/html/5783.html" rel="external">"Clinical features and diagnosis of supraventricular tachycardia (SVT) in children", section on 'Electrocardiogram'</a>.)</p><p>An echocardiogram should be obtained to assess for structural heart disease since SVT can be associated with congenital heart disease (21 percent of patients referred for catheter ablation in one series) [<a href="#rid32">32</a>].</p><p>The evaluation of children with SVT is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5783.html" rel="external">"Clinical features and diagnosis of supraventricular tachycardia (SVT) in children", section on 'Diagnosis'</a>.)</p><p class="headingAnchor" id="H3239810245"><span class="h1">REFERRAL</span><span class="headingEndMark"> — </span>Infants and children with preexcitation on electrocardiogram (ECG) or documented SVT should be referred to a pediatric cardiologist/electrophysiologist to guide the diagnostic evaluation and to discuss risk assessment and management options.</p><p>Urgent referral is warranted for children who present with SVT associated with any of the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Syncope</p><p class="bulletIndent1"><span class="glyph">●</span>Heart failure</p><p class="bulletIndent1"><span class="glyph">●</span>Incessant tachycardia</p><p class="bulletIndent1"><span class="glyph">●</span>Other concerning cardiac finding (eg, depressed ventricular function on echocardiogram)</p><p></p><p>In most other circumstances, referral can be done electively on an outpatient basis.</p><p class="headingAnchor" id="H858314050"><span class="h1">TREATMENT TO PREVENT SUPRAVENTRICULAR TACHYCARDIA RECURRENCES</span><span class="headingEndMark"> — </span>Options for chronic management of SVT include expectant management, pharmacologic therapy, and catheter ablation. Each approach has advantages and disadvantages. The specific approach should be tailored to the individual patient based upon age and severity of symptoms  (<a class="graphic graphic_algorithm graphicRef51645" href="/z/d/graphic/51645.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H119738878"><span class="h2">Infants &lt;1 year</span><span class="headingEndMark"> — </span>For infants with SVT, we suggest prophylactic pharmacologic therapy with <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a>. Expectant management is an alternative option after the first episode if the infant is asymptomatic and has normal ventricular function. We generally prefer initial pharmacologic therapy over expectant management because infants cannot complain of palpitations, and therefore detection of recurrences of SVT may be delayed even if parents are instructed to monitor the heart rate. Thus, infants are more likely to develop signs and symptoms of heart failure compared with older children [<a href="#rid6">6</a>]. Catheter ablation is generally not an option in infants, because the risk of complications is unacceptably high.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prophylactic medication (preferred)</strong> – We suggest treatment with a beta blocker as the first-line agent for chronic management of SVT in infants. This is based largely on the side effect profile of beta blockers, which is generally more favorable than that of other antiarrhythmic drugs. Observational data, clinical experience, and a single randomized clinical trial support this practice [<a href="#rid46">46-50</a>]. The preferred beta blocker for infants &lt;12 months is <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a> (2 to 4 mg/kg per day orally divided into four doses). (See <a class="local">'First-line prophylactic therapy (beta blocker)'</a> below.)</p><p></p><p class="bulletIndent1">The duration of therapy in infants &lt;1 year is variable. In a multicenter cohort study of 278 infants treated for either six months or one year, no difference in SVT recurrence rate was seen over one year (12 percent in both groups) [<a href="#rid51">51</a>]. Independent risk factors for recurrence included combination antiarrhythmic regimens, WPW, and age &gt;1 month at presentation. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Expectant management</strong> – Expectant management is an option for infants who are asymptomatic without hemodynamic compromise or ventricular dysfunction. However, this approach is chosen less often for infants because recurrences of SVT are more challenging to detect in this age group compared with older children. If expectant management is selected, the infant is monitored for 24 hours and teaching is provided to the parents prior to hospital discharge, as described below. (See <a class="local">'First episode, minimal symptoms'</a> below.)</p><p></p><p class="headingAnchor" id="H484057085"><span class="h2">Children ≥1 year</span><span class="headingEndMark"> — </span>For children ≥1 year, the approach to chronic management depends on the severity of symptoms and the size of the child  (<a class="graphic graphic_algorithm graphicRef51645" href="/z/d/graphic/51645.html" rel="external">algorithm 2</a>).</p><p class="headingAnchor" id="H2054339873"><span class="h3">First episode, minimal symptoms</span><span class="headingEndMark"> — </span>We typically manage patients expectantly following the first episode of SVT if the child has no or only minimal symptoms and there is no hemodynamic instability or ventricular dysfunction. For such patients, we monitor the child for at least 24 hours, teach the parents how to check the heart rate, and instruct them in methods for terminating SVT episodes using vagal maneuvers (eg, applying an ice bag to the face, performing the Valsalva maneuver, assuming a head-down position, and other techniques). (See <a class="local">'Vagal maneuvers'</a> above.)</p><p>The rationale for this approach is that some patients (particularly those who are &lt;5 years old at initial presentation) may outgrow the SVT and may not require chronic therapy, which may be associated with side effects. (See  <a class="medical medical_review" href="/z/d/html/5783.html" rel="external">"Clinical features and diagnosis of supraventricular tachycardia (SVT) in children", section on 'Natural history'</a>.)</p><p>As discussed above, this approach is used less often in infants because recurrences of SVT are more challenging to detect in this age group. (See <a class="local">'Infants &lt;1 year'</a> above.)</p><p class="headingAnchor" id="H17"><span class="h3">Recurrent and/or symptomatic supraventricular tachycardia episodes</span><span class="headingEndMark"> — </span>For children who have recurrent and/or symptomatic SVT episodes, we suggest intervention to prevent further recurrences. The choice of intervention depends on the size of the child; radiofrequency ablation (RFA) is generally reserved for patients ≥15 kg because of the increased risk of complications with RFA in small children.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children &lt;15 kg</strong> – For infants and young children &lt;15 kg who have frequent episodes of SVT or who become symptomatic during infrequent episodes, we suggest prophylactic medical therapy. The objective of medical treatment is to prevent episodes of SVT or to lessen symptoms during a recurrence. In our practice, we use long-term daily medication with a beta blocker for such children. We typically use a long-acting beta blocker such as <a class="drug drug_pediatric" data-topicid="12848" href="/z/d/drug information/12848.html" rel="external">atenolol</a> or <a class="drug drug_pediatric" data-topicid="12625" href="/z/d/drug information/12625.html" rel="external">nadolol</a> in children &gt;1 year old. Both are given at a dose of 1 to 2 mg/kg per day orally. (See <a class="local">'First-line prophylactic therapy (beta blocker)'</a> below.)</p><p></p><p class="bulletIndent1">Another form of treatment is "pulsed" or "cocktail" therapy, in which the patient takes an antiarrhythmic drug only during an episode of SVT in order to terminate the arrhythmia [<a href="#rid6">6,52,53</a>]; however, we do not generally use this approach.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Children ≥15 kg</strong> – In children who are ≥15 kg, we suggest RFA rather than chronic antiarrhythmic medication therapy. RFA is an effective treatment for most types of SVT, and it avoids the adverse effects of chronic pharmacologic therapy. (See <a class="local">'Catheter ablation'</a> below.)</p><p></p><p class="headingAnchor" id="H19"><span class="h2">Failure of initial medical therapy</span><span class="headingEndMark"> — </span>For patients managed with pharmacologic therapy who do not achieve adequate control of SVT with first-line therapy, options for second-line therapy include <a class="drug drug_pediatric" data-topicid="13302" href="/z/d/drug information/13302.html" rel="external">flecainide</a>, <a class="drug drug_pediatric" data-topicid="12802" href="/z/d/drug information/12802.html" rel="external">sotalol</a>, and <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> [<a href="#rid54">54-60</a>]. (See <a class="local">'Second-line agents'</a> below.)</p><p>RFA is another option for children who fail initial medical therapy, and this is the preferred approach for children ≥15 kg. RFA is generally not performed in children &lt;15 kg unless the SVT is refractory to medical therapy or there are intolerable adverse effects from pharmacologic therapy. (See <a class="local">'Catheter ablation'</a> below.)</p><p>In one study, factors that predicted poor response to initial therapy included young age at presentation (&lt;1 month), ventricular dysfunction at presentation, and slow retrograde conduction properties of the accessory pathway [<a href="#rid61">61</a>].</p><p class="headingAnchor" id="H3320450319"><span class="h1">TREATMENT MODALITIES FOR PREVENTIVE THERAPY</span><span class="headingEndMark"> — </span>Treatment options for long-term control of SVT include pharmacologic therapy and ablation of the reentrant pathway. The approach is tailored to the individual patient based upon age and severity of symptoms, as summarized in the figure and described above  (<a class="graphic graphic_algorithm graphicRef51645" href="/z/d/graphic/51645.html" rel="external">algorithm 2</a>). (See <a class="local">'Treatment to prevent supraventricular tachycardia recurrences'</a> above.)</p><p class="headingAnchor" id="H1736277313"><span class="h2">Pharmacologic therapy</span></p><p class="headingAnchor" id="H1746229116"><span class="h3">First-line prophylactic therapy (beta blocker)</span><span class="headingEndMark"> — </span>For most patients who require pharmacologic prophylaxis for chronic SVT management, we suggest a beta blocker rather than <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">digoxin</a> or an antiarrhythmic drug. Our preference is based largely on the more favorable side effect profile of beta blockers compared with other antiarrhythmic drugs.</p><p>The choice of beta blocker is based upon age:</p><p class="bulletIndent1"><span class="glyph">●</span>Infants – In infants, we use <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a> (2 to 4 mg/kg per day orally divided into four doses)</p><p class="bulletIndent1"><span class="glyph">●</span>Older children – In older children, we use a longer-acting beta blocker such as <a class="drug drug_pediatric" data-topicid="12848" href="/z/d/drug information/12848.html" rel="external">atenolol</a> or <a class="drug drug_pediatric" data-topicid="12625" href="/z/d/drug information/12625.html" rel="external">nadolol</a> (both are given at a dose of 1 to 2 mg/kg per day orally)</p><p></p><p>Side effects of beta blockers include hypotension, bradycardia, emotional disturbances, and nightmares. (See  <a class="medical medical_review" href="/z/d/html/967.html" rel="external">"Major side effects of beta blockers"</a>.)</p><p>Beta blocker therapy has generally replaced <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">digoxin</a>, which was commonly used to treat SVT in the past, because beta blockers are better tolerated and do not require therapeutic drug monitoring. The rate of SVT recurrence in infants treated with <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a> appears to be comparable with that of digoxin [<a href="#rid49">49,50</a>]. In a multicenter clinical trial involving 71 infants with SVT randomized to propranolol or digoxin, rates of SVT recurrence were similar in both groups (33 and 34 percent, respectively) [<a href="#rid49">49</a>]. No deaths and no serious adverse events related to study medications were observed.</p><p>In a retrospective study evaluating data from the Pediatric Health Information System (PHIS) database (2003 to 2013) that included 851 infants &lt;1 year old (44 percent were &lt;30 days old) hospitalized for management of SVT, 73 percent were prescribed antiarrhythmic therapy [<a href="#rid62">62</a>]. Single-agent therapy with <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a> was the most common treatment (44 percent), followed by <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">digoxin</a> (24 percent) and <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> (16 percent); multiagent therapy was used in 10 percent of patients. The rate of readmission for SVT within 30 days of hospital discharge was low in this cohort (5 percent) and was similar among patients discharged on propranolol compared with other agents or no therapy.</p><p>Another study using data from the PHIS database (2004 to 2015) identified 1339 neonates ≤2 days old who were treated with antiarrhythmic medication(s) for SVT or other nonventricular dysrhythmia [<a href="#rid63">63</a>]. <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">Propranolol</a> use steadily increased during the study period, while <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">digoxin</a> use decreased. In propensity score matching analysis, mortality appeared to be lower among patients treated with propranolol compared with digoxin; however, the finding was not significantly significant (odds ratio 0.64, 95% CI 0.28-1.41).</p><p>In a single-center study of 287 infants (median age 17 days), therapy with high-dose enteral <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a> (mean dose 3.6 mg/kg per day) controlled SVT in 67 percent of patients [<a href="#rid46">46</a>]. In this cohort, control of SVT was maintained during outpatient therapy in approximately 90 percent of patients continuing on the medication. Only one patient experienced a clinically significant adverse event (bradycardia) during institution of therapy that resulted in discontinuation of the medication. Patients who failed monotherapy with propranolol were more likely to have congenital heart disease or Wolff-Parkinson-White (WPW) syndrome and were switched successfully to <a class="drug drug_pediatric" data-topicid="12802" href="/z/d/drug information/12802.html" rel="external">sotalol</a> (n = 53), <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">digoxin</a> (n = 12), <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> (n = 7), <a class="drug drug_pediatric" data-topicid="13302" href="/z/d/drug information/13302.html" rel="external">flecainide</a> (n = 7), or combination therapy.</p><p class="headingAnchor" id="H2176294208"><span class="h3">Second-line agents</span><span class="headingEndMark"> — </span>For patients who do not achieve adequate control of SVT with beta blocker therapy, options for second-line pharmacologic therapy include <a class="drug drug_pediatric" data-topicid="13302" href="/z/d/drug information/13302.html" rel="external">flecainide</a>, <a class="drug drug_pediatric" data-topicid="12802" href="/z/d/drug information/12802.html" rel="external">sotalol</a>, and <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> [<a href="#rid54">54-60</a>]. <a class="drug drug_pediatric" data-topicid="12879" href="/z/d/drug information/12879.html" rel="external">Verapamil</a> should <strong>not</strong> be used in infants &lt;1 year and children with WPW syndrome. These restrictions limit verapamil's use as a second-line agent in pediatric patients. <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">Digoxin</a> is rarely used to treat SVT in contemporary practice. It was commonly used in the past, but it has been replaced by other more effective and better-tolerated agents.</p><p>Second-line drugs may be effective alone or in combination. Their efficacy for the treatment of refractory SVT in children is supported by small case series [<a href="#rid54">54-60</a>].</p><p>The side effects of these drugs are generally more serious than those seen with beta blockers. The side effects of each agent are discussed in greater detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="13302" href="/z/d/drug information/13302.html" rel="external">Flecainide</a> – Flecainide is generally well tolerated, but it can be proarrhythmic and is associated with a variety of noncardiac side effects, including dizziness, blurred vision, headache, and nausea. (See  <a class="medical medical_review" href="/z/d/html/86747.html" rel="external">"Major side effects of class I antiarrhythmic drugs", section on 'Flecainide'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12802" href="/z/d/drug information/12802.html" rel="external">Sotalol</a> – Sotalol is generally well tolerated. Major cardiac side effects bradycardia and proarrhythmia. Noncardiac side effects may include fatigue, weakness, and dizziness. (See  <a class="medical medical_review" href="/z/d/html/925.html" rel="external">"Clinical uses of sotalol", section on 'Major side effects'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">Amiodarone</a> – Adverse effects associated with amiodarone are summarized in the table and are discussed separately  (<a class="graphic graphic_table graphicRef126072" href="/z/d/graphic/126072.html" rel="external">table 2</a>). (See  <a class="medical medical_review" href="/z/d/html/931.html" rel="external">"Amiodarone: Adverse effects, potential toxicities, and approach to monitoring"</a>.)</p><p></p><p>There are few data comparing these drugs in children with SVT. In the available case series, success rates of these agents ranged from 20 to 100 percent [<a href="#rid54">54-60</a>]. In a case series of 78 infants with refractory SVT (approximately one-half had underlying congenital heart disease), 90 percent achieved control of SVT with high-dose <a class="drug drug_pediatric" data-topicid="12802" href="/z/d/drug information/12802.html" rel="external">sotalol</a> therapy (median dose 152 mg/m<sup>2</sup> per day, range 65 to 244 mg/m<sup>2</sup> per day) [<a href="#rid64">64</a>]. No patients experienced clinically significant QTc prolongation or proarrhythmia. In another retrospective study of 33 infants with SVT (all cases were due to atrioventricular [AV] reentrant tachycardia) treated initially with <a class="drug drug_pediatric" data-topicid="13230" href="/z/d/drug information/13230.html" rel="external">digoxin</a>, 58 percent had multiple recurrences on digoxin and were transitioned to <a class="drug drug_pediatric" data-topicid="13302" href="/z/d/drug information/13302.html" rel="external">flecainide</a>, which controlled the SVT in all cases [<a href="#rid54">54</a>]. In a report of 74 children with recurrent SVT treated with oral flecainide (n = 47) or oral <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a> (n = 27), the proportion of patients who achieved complete or partial success was similar in both groups (81 and 78 percent, respectively) [<a href="#rid60">60</a>]. Of the five children who failed amiodarone and subsequently switched to flecainide, four achieved success. Side effects were generally minor and were less common with flecainide compared with amiodarone (9 versus 22 percent).</p><p>Combination therapy is generally reserved for patients with difficult-to-control arrhythmia and requires careful monitoring for proarrhythmic effects [<a href="#rid58">58</a>]. The use of combinations of drugs is variable from institution to institution and patient to patient.</p><p class="headingAnchor" id="H20"><span class="h2">Catheter ablation</span><span class="headingEndMark"> — </span>Catheter ablation is the definitive therapy for SVT. As discussed in the following sections, success rates at most experienced centers are &gt;90 percent and complication rates are low. However, the risk of complications is increased in infants and small children, which limits its use in that population.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Indications</strong> – We suggest radiofrequency ablation (RFA) for children who are ≥15 kg and who either have frequent episodes of SVT or become symptomatic during infrequent episodes  (<a class="graphic graphic_algorithm graphicRef51645" href="/z/d/graphic/51645.html" rel="external">algorithm 2</a>). For such patients, elective RFA is generally preferred over chronic antiarrhythmic therapy because it avoids the adverse effects of pharmacologic therapy. However, the choice of treatment should be based on shared decision-making with the family.</p><p></p><p class="bulletIndent1">We agree with the following clinical indications for RFA developed by the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Documented recurrent or persistent SVT that is associated with ventricular dysfunction (in patients ≥15 kg)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Documented recurrent or persistent SVT when medical therapy is either not effective or is associated with intolerable adverse effects (in patients of any size)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Documented recurrent or persistent SVT (in patients ≥15 kg) when the family wishes to avoid chronic antiarrhythmic medications</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Documented recurrent SVT that is associated with acute hemodynamic compromise (hypotension or syncope) or that requires emergency medical care or electrical cardioversion (in patients ≥15 kg)</p><p></p><p class="bulletIndent1">Additional indications are beyond the scope of this topic and are based on other clinical presentations and electrophysiologic (EP) testing, as detailed in the <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.heartrhythmjournal.com%2Farticle%2FS1547-5271%2816%2900172-7%2Fpdf&amp;token=rvTukyyIVowC5RKz8kYMi3XD%2FYfDH1khO%2FaqFYkkEcFfTGcB6Af%2F4HsDvq2pOc2zdTrmHqPEyl7rhFmZ9HxXTxcenGHQy818PuPetNR%2FI14%3D&amp;TOPIC_ID=5782" target="_blank">PACES/HRS consensus statement</a> [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">Although there are data documenting the efficacy of RFA in smaller children [<a href="#rid66">66-68</a>], we generally avoid the procedure in patients &lt;15 kg unless the patient is refractory to medical therapy because of increased risk of complications in small children [<a href="#rid69">69,70</a>].</p><p></p><p class="bulletIndent1">The role of RFA in asymptomatic patients with WPW pattern on electrocardiogram remains controversial. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Asymptomatic patients'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Technique</strong> – RFA is performed as part of an invasive EP study. Sedation is provided to minimize discomfort and prevent patient movement during the procedure; general anesthesia is often necessary for young children [<a href="#rid6">6,65</a>].</p><p></p><p class="bulletIndent1">The EP study is performed in two stages:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Determining the mechanism of SVT and localizing the pathway – In this stage, transvenous catheter electrodes are inserted and manipulated for pacing and recording. The pattern of recordings obtained during normal sinus rhythm, in response to pacing, and during the SVT (if it can be induced) is used to make a definitive diagnosis of the mechanism of the SVT.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Ablating the pathway – After the mechanism of SVT is determined and the accessory pathway or AV nodal pathway is localized, a modified catheter is used that can deliver radiofrequency energy, which cauterizes the myocardial tissue and destroys the pathway. The standard energy source used for catheter ablation is radiofrequency current. Cryoenergy is an alternative that has been used in children with atrioventricular nodal reentrant tachycardia (AVNRT) [<a href="#rid71">71-74</a>]. In contrast, direct current ablation, which was employed prior to the development of RFA, was associated with a high incidence of complications and is no longer used clinically [<a href="#rid75">75,76</a>].</p><p></p><p class="bulletIndent1">The technical details of catheter ablation are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/1007.html" rel="external">"Overview of catheter ablation of cardiac arrhythmias"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – In the available reports of RFA in children, acute procedural success rates ranged from 80 to 100 percent and recurrences occurred in 5 to 20 percent [<a href="#rid32">32,69,70,77-80</a>]. Success rates have generally improved since the early era of RFA in the 1990s, and rates of recurrence and complications have declined [<a href="#rid32">32,81,82</a>]. In the contemporary era, success rates for pediatric RFA in most experienced centers are &gt;90 percent and complications occur in &lt;5 percent of cases.</p><p></p><p class="bulletIndent1">The success of RFA depends in part on the mechanism of SVT and the location of the accessory pathway. In a study from a multicenter pediatric RFA registry involving &gt;2500 patients (1800 with accessory pathways, 800 with AVNRT), success rates were 94 percent for patients with accessory pathways and 97 percent for those with AVNRT [<a href="#rid78">78</a>]. For patients with accessory pathways, the highest success rates were seen in children with pathways located in the left free wall (98 percent), whereas success rates were somewhat lower for patients with right free wall, right septal, and left septal pathways (90, 89, and 88 percent, respectively). A study evaluating data from three large registries from three distinct eras (the pediatric RFA registry [1994 to 1997], the Prospective Assessment After Pediatric Cardiac Ablation registry [2002 to 2004], and the MAP-IT registry [2014 to 2016]) found that acute success rates improved over time for both accessory and slow pathway substrates while fluoroscopy and procedural time decreased [<a href="#rid82">82</a>]. Long-term follow-up studies from centers in Europe reported recurrence rates of 10 to 15 percent at follow-up of two to five years after RFA [<a href="#rid79">79,81</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Complications</strong> – Procedural complications associated with RFA are uncommon, occurring in &lt;5 percent of cases [<a href="#rid70">70,78,79,81,82</a>]. In a report from the MAP-IT registry including 1417 procedures performed at 12 North American centers between 2014 and 2016, the reported complication rate was 3.6 percent [<a href="#rid82">82</a>]. Most studies assessing complications of RFA use a fairly broad definition, including major, minor, and transient adverse events.</p><p></p><p class="bulletIndent1">In earlier registry studies, EP study-related complications were reported in 2.9 percent of procedures and ablation-related complications were reported in 3.2 percent [<a href="#rid70">70,78</a>]. The most common EP study-related complication was hematoma at the catheter insertion site (1.4 percent). The most common ablation-related complication was AV block (0.7 to 1.3 percent), which occurred only in patients with AVNRT or septal accessory pathways and did not occur in patients undergoing ablation of accessory pathways located in the right or left free wall. Other complications included right bundle branch block (0.7 percent), perforation and/or pericardial effusion (0.1 to 0.7 percent), brachial plexus injury (0.2 to 0.3 percent), valvular regurgitation (0.3 percent), emboli (0 to 0.2 percent), and pneumothorax (0 to 0.2 percent). There were four procedure-related deaths in the earliest cohort (0.1 percent) [<a href="#rid70">70</a>] and no deaths in the later cohort [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1">Risk factors for complications based largely on the experience reported in the Pediatric RFA registry studies from the 1990s to early 2000s include patient age &lt;4 years, patient weight &lt;15 kg, and center inexperience with the procedure [<a href="#rid69">69,70,83,84</a>].</p><p></p><p class="headingAnchor" id="H26"><span class="h2">Surgical therapy</span><span class="headingEndMark"> — </span>Though surgical ablation is an effective treatment for drug-refractory SVT, it has largely been replaced by RFA. In the modern era, surgery is reserved for the rare instances in which an arrhythmia is refractory to attempted RFA and those occasions in which another cardiac surgical procedure is planned as part of the patient's management (eg, tricuspid valve repair for Ebstein anomaly) [<a href="#rid85">85-87</a>]. (See  <a class="medical medical_review" href="/z/d/html/996.html" rel="external">"Treatment of arrhythmias associated with the Wolff-Parkinson-White syndrome", section on 'Surgical ablation'</a> and  <a class="medical medical_review" href="/z/d/html/108790.html" rel="external">"Ebstein anomaly: Management and prognosis", section on 'Surgical or catheter intervention'</a>.)</p><p class="headingAnchor" id="H62714099"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Most infants and children who present with SVT recover fully; however, recurrences are fairly common.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>SVT recurrence</strong> – Most patients experience at least one recurrence of SVT after the initial episode. The likelihood of recurrence depends on the age at presentation, mechanism of SVT, and treatment given.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who present in infancy with atrioventricular reentrant tachycardia (which is the most common mechanism of SVT in children), symptoms often resolve by one year of age, though recurrences can occur later in life [<a href="#rid88">88</a>]. The natural histories of different types of SVT are discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5783.html" rel="external">"Clinical features and diagnosis of supraventricular tachycardia (SVT) in children", section on 'Natural history'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>As discussed above, approximately 10 to 15 percent of patients who have undergone catheter ablation experience late recurrences. (See <a class="local">'Catheter ablation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mortality</strong> – The risk of mortality associated with SVT is very low, though it is greater in patients with underlying structural heart disease (eg, congenital heart disease or cardiomyopathy) compared with those without structural heart disease [<a href="#rid89">89,90</a>]. In a population-based study from Taiwan that included 2021 infants and children with SVT with average follow-up of 10.8 years, the annual mortality rate was 0.2 percent per year [<a href="#rid90">90</a>]. Mortality was greatest among patients with congenital heart disease or cardiomyopathy. Similar findings were noted in a retrospective study of 1755 hospitalized pediatric and young adult patients (age &lt;25 years) with SVT, in which hospital mortality was 6 percent among patients with structural heart disease compared with 1 percent in patients without structural heart disease [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1">Patients with Wolff-Parkinson-White syndrome are at increased risk for sudden cardiac death, though the overall risk is low [<a href="#rid91">91</a>]. The cause of sudden cardiac death is not SVT but rather ventricular fibrillation, which can occur during an episode of atrial fibrillation if there is rapid conduction to the ventricle. This issue is discussed in greater detail separately. (See  <a class="medical medical_review" href="/z/d/html/5783.html" rel="external">"Clinical features and diagnosis of supraventricular tachycardia (SVT) in children", section on 'Ventricular fibrillation and sudden death'</a> and  <a class="medical medical_review" href="/z/d/html/962.html" rel="external">"Wolff-Parkinson-White syndrome: Anatomy, epidemiology, clinical manifestations, and diagnosis", section on 'Mechanism of and risk factors for SCD in WPW'</a>.)</p><p></p><p class="headingAnchor" id="H1725553293"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/116933.html" rel="external">"Society guideline links: Arrhythmias in children"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/117107.html" rel="external">"Society guideline links: Basic and advanced cardiac life support in children"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/116931.html" rel="external">"Society guideline links: Supraventricular arrhythmias"</a>.)</p><p class="headingAnchor" id="H29"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acute management</strong> – The acute management of supraventricular tachycardia (SVT) in infants and children consists of interventions to terminate the tachyarrhythmia with ongoing assessment the patient's clinical status. The urgency and choice of treatment depend on the patient's hemodynamic stability  (<a class="graphic graphic_table graphicRef53559" href="/z/d/graphic/53559.html" rel="external">table 1</a>) (see <a class="local">'Acute management'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Unstable SVT</strong> – Synchronized direct current cardioversion with 0.5 to 1 J/kg is the definitive treatment for SVT in children who are hemodynamically unstable  (<a class="graphic graphic_table graphicRef53559" href="/z/d/graphic/53559.html" rel="external">table 1</a> and <a class="graphic graphic_algorithm graphicRef129940" href="/z/d/graphic/129940.html" rel="external">algorithm 1</a>). The dose can be increased to 2 J/kg if the lower dose is ineffective. <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">Adenosine</a> may be given while preparing to cardiovert if the drug is readily available and the child has intravenous (IV) access. Similarly, vagal maneuvers can be attempted while preparing for cardioversion or drug therapy, but cardioversion should not be delayed to administer vagal maneuvers. (See <a class="local">'Unstable patients'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Stable SVT</strong> – In patients who are hemodynamically stable, additional time can be given to evaluate the rhythm. The approach to management of SVT in stable patients is as follows  (<a class="graphic graphic_table graphicRef53559" href="/z/d/graphic/53559.html" rel="external">table 1</a>) (see <a class="local">'Stable patients'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We recommend vagal maneuvers as the initial intervention rather than pharmacologic therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). For an infant, this consists of applying an ice bag to the face for 15 to 30 seconds. In older children, vagal maneuvers include bearing down (Valsalva maneuver), blowing into an occluded straw, or assuming a head-down position for 15 to 20 seconds. (See <a class="local">'Vagal maneuvers'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If vagal maneuvers are ineffective, we suggest IV <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a> rather than other antiarrhythmic drugs (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Adenosine is administered at a dose of 0.1 mg/kg (maximum 6 mg), followed by a rapid <a class="drug drug_pediatric" data-topicid="12796" href="/z/d/drug information/12796.html" rel="external">saline</a> flush. If no response is seen within two minutes, the dose should be doubled (ie, 0.2 mg/kg IV, maximum 12 mg). (See <a class="local">'First-line therapy (adenosine)'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For SVT that is refractory to <a class="drug drug_pediatric" data-topicid="13258" href="/z/d/drug information/13258.html" rel="external">adenosine</a>, choices for IV antiarrhythmic therapy include <a class="drug drug_pediatric" data-topicid="12732" href="/z/d/drug information/12732.html" rel="external">procainamide</a> and <a class="drug drug_pediatric" data-topicid="12587" href="/z/d/drug information/12587.html" rel="external">amiodarone</a>. These drugs have potential for serious adverse effects, and, therefore, consultation with a pediatric cardiologist is advised. <a class="drug drug_pediatric" data-topicid="12879" href="/z/d/drug information/12879.html" rel="external">Verapamil</a> is another option; however, it should <strong>not</strong> be used in infants &lt;1 year old or patients with known or suspected Wolff-Parkinson-White (WPW) syndrome. Beta blocker therapy (eg, IV <a class="drug drug_pediatric" data-topicid="13279" href="/z/d/drug information/13279.html" rel="external">esmolol</a> or oral <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a>) is an alternative to IV antiarrhythmic therapy if the SVT appears to be well tolerated (ie, hemodynamically stable and no symptoms) and the patient is in a closely monitored setting. (See <a class="local">'Supraventricular tachycardia refractory to adenosine'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation after the episode</strong> – After the acute episode is terminated, an electrocardiogram (ECG) and echocardiogram should be performed to look for evidence of WPW syndrome  (<a class="graphic graphic_waveform graphicRef75578" href="/z/d/graphic/75578.html" rel="external">waveform 1</a>) and structural heart disease. (See <a class="local">'Evaluation after the acute episode'</a> above and  <a class="medical medical_review" href="/z/d/html/5783.html" rel="external">"Clinical features and diagnosis of supraventricular tachycardia (SVT) in children", section on 'Diagnosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic management</strong> – Options for chronic management of SVT include expectant management, pharmacologic therapy, and catheter ablation. The approach is tailored to the individual patient based upon age and severity of symptoms  (<a class="graphic graphic_algorithm graphicRef51645" href="/z/d/graphic/51645.html" rel="external">algorithm 2</a>) (see <a class="local">'Treatment to prevent supraventricular tachycardia recurrences'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Infants &lt;1 year</strong> – For most infants with SVT, we suggest prophylactic pharmacologic therapy rather than expectant management (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). However, expectant management is a reasonable option after the first episode if the infant is asymptomatic and hemodynamically stable with normal ventricular function. When prophylactic therapy is used, we suggest a beta blocker (eg, <a class="drug drug_pediatric" data-topicid="12744" href="/z/d/drug information/12744.html" rel="external">propranolol</a>) as the first-line agent rather than other drugs (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). This is based largely on the side effect profile of beta blockers, which is generally more favorable than that of other antiarrhythmic drugs. (See <a class="local">'Infants &lt;1 year'</a> above and <a class="local">'First-line prophylactic therapy (beta blocker)'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Children ≥1 year</strong> – For children ≥1 year, the approach to chronic management depends on the severity of symptoms and the size of the child  (<a class="graphic graphic_algorithm graphicRef51645" href="/z/d/graphic/51645.html" rel="external">algorithm 2</a>):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>First episode, minimal symptoms</strong> – For patients presenting after the first episode of SVT who have no or only minimal symptoms and who have no evidence of hemodynamic instability or ventricular dysfunction, we suggest expectant management rather than pharmacologic or catheter-based intervention (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The child is monitored for at least 24 hours, and the parents are taught how to check the heart rate. The parents (and child, if able) are also taught how to use vagal maneuvers (eg, applying an ice bag to the face, performing the Valsalva maneuver, assuming a head-down position, and other techniques) to assist in self-termination of SVT if it recurs. (See <a class="local">'First episode, minimal symptoms'</a> above and <a class="local">'Vagal maneuvers'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span><strong>Recurrent and/or symptomatic SVT episodes</strong> – For children who have frequent episodes of SVT or who become symptomatic during infrequent episodes, we suggest intervention to prevent further recurrences (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). The choice of intervention depends on the size of the child. For most infants and young children &lt;15 kg, we suggest prophylactic medical therapy rather than catheter ablation (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Pharmacologic therapy is preferred in this setting because the risk of complications with catheter ablation is increased in small children. We suggest a beta blocker (eg, <a class="drug drug_pediatric" data-topicid="12848" href="/z/d/drug information/12848.html" rel="external">atenolol</a>, <a class="drug drug_pediatric" data-topicid="12625" href="/z/d/drug information/12625.html" rel="external">nadolol</a>) as the first-line agent rather than other drugs (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). For children who are ≥15 kg, we suggest catheter ablation rather than chronic antiarrhythmic medication (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Children ≥1 year'</a> above and <a class="local">'First-line prophylactic therapy (beta blocker)'</a> above and <a class="local">'Catheter ablation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outcome</strong> – Most infants and children who present with SVT recover fully; however, recurrences are common. The risk of mortality associated with SVT is very low. (See <a class="local">'Outcome'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Josephson ME, Wellens HJ. Differential diagnosis of supraventricular tachycardia. Cardiol Clin 1990; 8:411.</a></li><li><a class="nounderline abstract_t">Kleinman ME, Chameides L, Schexnayder SM, et al. Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122:S876.</a></li><li><a class="nounderline abstract_t">de Caen AR, Berg MD, Chameides L, et al. Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2015; 132:S526.</a></li><li><a class="nounderline abstract_t">Rodriguez E, Jordan R. Contemporary trends in pediatric sedation and analgesia. Emerg Med Clin North Am 2002; 20:199.</a></li><li><a class="nounderline abstract_t">Guidelines for the elective use of conscious sedation, deep sedation, and general anesthesia in pediatric patients. Committee on Drugs. Section on anesthesiology. Pediatrics 1985; 76:317.</a></li><li><a class="nounderline abstract_t">Kugler JD, Danford DA. Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. J Pediatr 1996; 129:324.</a></li><li><a class="nounderline abstract_t">Roth A, Elkayam I, Shapira I, et al. Effectiveness of prehospital synchronous direct-current cardioversion for supraventricular tachyarrhythmias causing unstable hemodynamic states. Am J Cardiol 2003; 91:489.</a></li><li><a class="nounderline abstract_t">Lewis J, Arora G, Tudorascu DL, et al. Acute Management of Refractory and Unstable Pediatric Supraventricular Tachycardia. J Pediatr 2017; 181:177.</a></li><li><a class="nounderline abstract_t">Clausen H, Theophilos T, Jackno K, Babl FE. Paediatric arrhythmias in the emergency department. Emerg Med J 2012; 29:732.</a></li><li><a class="nounderline abstract_t">Luber S, Brady WJ, Joyce T, Perron AD. Paroxysmal supraventricular tachycardia: outcome after ED care. Am J Emerg Med 2001; 19:40.</a></li><li><a class="nounderline abstract_t">Bisset GS 3rd, Gaum W, Kaplan S. The ice bag: a new technique for interruption of supraventricular tachycardia. J Pediatr 1980; 97:593.</a></li><li><a class="nounderline abstract_t">Garson A Jr, Gillette PC, McNamara DG. Supraventricular tachycardia in children: clinical features, response to treatment, and long-term follow-up in 217 patients. J Pediatr 1981; 98:875.</a></li><li><a class="nounderline abstract_t">Müller G, Deal BJ, Benson DW Jr. "Vagal maneuvers" and adenosine for termination of atrioventricular reentrant tachycardia. Am J Cardiol 1994; 74:500.</a></li><li><a class="nounderline abstract_t">Sreeram N, Wren C. Supraventricular tachycardia in infants: response to initial treatment. Arch Dis Child 1990; 65:127.</a></li><li><a class="nounderline abstract_t">Campbell M, Buitrago SR. BET 2: Ice water immersion, other vagal manoeuvres or adenosine for SVT in children. Emerg Med J 2017; 34:58.</a></li><li><a class="nounderline abstract_t">Overholt ED, Rheuban KS, Gutgesell HP, et al. Usefulness of adenosine for arrhythmias in infants and children. Am J Cardiol 1988; 61:336.</a></li><li><a class="nounderline abstract_t">Paul T, Bertram H, Bökenkamp R, Hausdorf G. Supraventricular tachycardia in infants, children and adolescents: diagnosis, and pharmacological and interventional therapy. Paediatr Drugs 2000; 2:171.</a></li><li><a class="nounderline abstract_t">Sherwood MC, Lau KC, Sholler GF. Adenosine in the management of supraventricular tachycardia in children. J Paediatr Child Health 1998; 34:53.</a></li><li><a class="nounderline abstract_t">Willerson JT. July 4, 2000. Circulation 2000; 102:1.</a></li><li><a class="nounderline abstract_t">Crosson JE, Etheridge SP, Milstein S, et al. Therapeutic and diagnostic utility of adenosine during tachycardia evaluation in children. Am J Cardiol 1994; 74:155.</a></li><li class="breakAll">Adenocard IV prescribing information. Astellas Pharma US, INc., February 2011. adenocard.com (Accessed on August 21, 2011).</li><li><a class="nounderline abstract_t">Strickberger SA, Man KC, Daoud EG, et al. Adenosine-induced atrial arrhythmia: a prospective analysis. Ann Intern Med 1997; 127:417.</a></li><li><a class="nounderline abstract_t">DeGroff CG, Silka MJ. Bronchospasm after intravenous administration of adenosine in a patient with asthma. J Pediatr 1994; 125:822.</a></li><li><a class="nounderline abstract_t">Bennett-Guerrero E, Young CC. Bronchospasm after intravenous adenosine administration. Anesth Analg 1994; 79:386.</a></li><li><a class="nounderline abstract_t">Losek JD, Endom E, Dietrich A, et al. Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review. Ann Emerg Med 1999; 33:185.</a></li><li><a class="nounderline abstract_t">Ellenbogen KA, Thames MD, DiMarco JP, et al. Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity. Circulation 1990; 81:821.</a></li><li><a class="nounderline abstract_t">Flyer JN, Zuckerman WA, Richmond ME, et al. Prospective Study of Adenosine on Atrioventricular Nodal Conduction in Pediatric and Young Adult Patients After Heart Transplantation. Circulation 2017; 135:2485.</a></li><li><a class="nounderline abstract_t">Till J, Shinebourne EA, Rigby ML, et al. Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br Heart J 1989; 62:204.</a></li><li><a class="nounderline abstract_t">Lenk M, Celiker A, Alehan D, et al. Role of adenosine in the diagnosis and treatment of tachyarrhythmias in pediatric patients. Acta Paediatr Jpn 1997; 39:570.</a></li><li><a class="nounderline abstract_t">Camm AJ, Garratt CJ. Adenosine and supraventricular tachycardia. N Engl J Med 1991; 325:1621.</a></li><li><a class="nounderline abstract_t">Ko JK, Deal BJ, Strasburger JF, Benson DW Jr. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol 1992; 69:1028.</a></li><li><a class="nounderline abstract_t">Tanel RE, Walsh EP, Triedman JK, et al. Five-year experience with radiofrequency catheter ablation: implications for management of arrhythmias in pediatric and young adult patients. J Pediatr 1997; 131:878.</a></li><li><a class="nounderline abstract_t">Alabed S, Sabouni A, Providencia R, et al. Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia. Cochrane Database Syst Rev 2017; 10:CD005154.</a></li><li><a class="nounderline abstract_t">Chang PM, Silka MJ, Moromisato DY, Bar-Cohen Y. Amiodarone versus procainamide for the acute treatment of recurrent supraventricular tachycardia in pediatric patients. Circ Arrhythm Electrophysiol 2010; 3:134.</a></li><li><a class="nounderline abstract_t">Perry JC, Fenrich AL, Hulse JE, et al. Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol. J Am Coll Cardiol 1996; 27:1246.</a></li><li><a class="nounderline abstract_t">Figa FH, Gow RM, Hamilton RM, Freedom RM. Clinical efficacy and safety of intravenous Amiodarone in infants and children. Am J Cardiol 1994; 74:573.</a></li><li><a class="nounderline abstract_t">Saul JP, Scott WA, Brown S, et al. Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial. Circulation 2005; 112:3470.</a></li><li><a class="nounderline abstract_t">Saharan S, Balaji S. Cardiovascular collapse during amiodarone infusion in a hemodynamically compromised child with refractory supraventricular tachycardia. Ann Pediatr Cardiol 2015; 8:50.</a></li><li><a class="nounderline abstract_t">Desai AD, Chun S, Sung RJ. The role of intravenous amiodarone in the management of cardiac arrhythmias. Ann Intern Med 1997; 127:294.</a></li><li><a class="nounderline abstract_t">Soult JA, Muñoz M, Lopez JD, et al. Efficacy and safety of intravenous amiodarone for short-term treatment of paroxysmal supraventricular tachycardia in children. Pediatr Cardiol 1995; 16:16.</a></li><li><a class="nounderline abstract_t">Drago F, Mazza A, Guccione P, et al. Amiodarone used alone or in combination with propranolol: a very effective therapy for tachyarrhythmias in infants and children. Pediatr Cardiol 1998; 19:445.</a></li><li><a class="nounderline abstract_t">Epstein ML, Kiel EA, Victorica BE. Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. Pediatrics 1985; 75:737.</a></li><li><a class="nounderline abstract_t">Garson A Jr. Medicolegal problems in the management of cardiac arrhythmias in children. Pediatrics 1987; 79:84.</a></li><li><a class="nounderline abstract_t">Stewart RB, Bardy GH, Greene HL. Wide complex tachycardia: misdiagnosis and outcome after emergent therapy. Ann Intern Med 1986; 104:766.</a></li><li><a class="nounderline abstract_t">Volkmann H, Dannberg G, Heinke M, Kühnert H. Termination of tachycardias by transesophageal electrical pacing. Pacing Clin Electrophysiol 1992; 15:1962.</a></li><li><a class="nounderline abstract_t">Barton AL, Moffett BS, Valdes SO, et al. Efficacy and safety of high-dose propranolol for the management of infant supraventricular tachyarrhythmias. J Pediatr 2015; 166:115.</a></li><li><a class="nounderline abstract_t">Gilljam T, Jaeggi E, Gow RM. Neonatal supraventricular tachycardia: outcomes over a 27-year period at a single institution. Acta Paediatr 2008; 97:1035.</a></li><li><a class="nounderline abstract_t">Seslar SP, Garrison MM, Larison C, Salerno JC. A multi-institutional analysis of inpatient treatment for supraventricular tachycardia in newborns and infants. Pediatr Cardiol 2013; 34:408.</a></li><li><a class="nounderline abstract_t">Sanatani S, Potts JE, Reed JH, et al. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. Circ Arrhythm Electrophysiol 2012; 5:984.</a></li><li><a class="nounderline abstract_t">Weindling SN, Saul JP, Walsh EP. Efficacy and risks of medical therapy for supraventricular tachycardia in neonates and infants. Am Heart J 1996; 131:66.</a></li><li><a class="nounderline abstract_t">Mecklin M, Linnanmäki A, Hiippala A, et al. Multicenter cohort study on duration of antiarrhythmic medication for supraventricular tachycardia in infants. Eur J Pediatr 2023; 182:1089.</a></li><li><a class="nounderline abstract_t">Benson DW Jr, Dunnigan A, Green TP, et al. Periodic procainamide for paroxysmal tachycardia. Circulation 1985; 72:147.</a></li><li><a class="nounderline abstract_t">Margolis B, DeSilva RA, Lown B. Episodic drug treatment in the management of paroxysmal arrhythmias. Am J Cardiol 1980; 45:621.</a></li><li><a class="nounderline abstract_t">O'Sullivan JJ, Gardiner HM, Wren C. Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants? J Am Coll Cardiol 1995; 26:991.</a></li><li><a class="nounderline abstract_t">Pongiglione G, Strasburger JF, Deal BJ, Benson DW Jr. Use of amiodarone for short-term and adjuvant therapy in young patients. Am J Cardiol 1991; 68:603.</a></li><li><a class="nounderline abstract_t">Etheridge SP, Craig JE, Compton SJ. Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants. Am Heart J 2001; 141:105.</a></li><li><a class="nounderline abstract_t">Fenrich AL Jr, Perry JC, Friedman RA. Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy. J Am Coll Cardiol 1995; 25:1195.</a></li><li><a class="nounderline abstract_t">Price JF, Kertesz NJ, Snyder CS, et al. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children &lt;1 year of age. J Am Coll Cardiol 2002; 39:517.</a></li><li><a class="nounderline abstract_t">Iwasawa S, Uyeda T, Saito M, et al. Efficacy and Safety of Low-Dose Amiodarone Therapy for Tachyarrhythmia in Congenital Heart Disease. Pediatr Cardiol 2018; 39:1016.</a></li><li><a class="nounderline abstract_t">Hill AC, Silka MJ, Bar-Cohen Y. A comparison of oral flecainide and amiodarone for the treatment of recurrent supraventricular tachycardia in children. Pacing Clin Electrophysiol 2019; 42:670.</a></li><li><a class="nounderline abstract_t">Sanatani S, Hamilton RM, Gross GJ. Predictors of refractory tachycardia in infants with supraventricular tachycardia. Pediatr Cardiol 2002; 23:508.</a></li><li><a class="nounderline abstract_t">Guerrier K, Shamszad P, Czosek RJ, et al. Variation in Antiarrhythmic Management of Infants Hospitalized with Supraventricular Tachycardia: A Multi-Institutional Analysis. Pediatr Cardiol 2016; 37:946.</a></li><li><a class="nounderline abstract_t">Bolin EH, Lang SM, Tang X, Collins RT. Propranolol Versus Digoxin in the Neonate for Supraventricular Tachycardia (from the Pediatric Health Information System). Am J Cardiol 2017; 119:1605.</a></li><li><a class="nounderline abstract_t">Knudson JD, Cannon BC, Kim JJ, Moffett BS. High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias. Pediatr Cardiol 2011; 32:896.</a></li><li><a class="nounderline abstract_t">Philip Saul J, Kanter RJ, WRITING COMMITTEE, et al. PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease: Developed in partnership with the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American Academy of Pediatrics (AAP), the American Heart Association (AHA), and the Association for European Pediatric and Congenital Cardiology (AEPC). Heart Rhythm 2016; 13:e251.</a></li><li><a class="nounderline abstract_t">An HS, Choi EY, Kwon BS, et al. Radiofrequency catheter ablation for supraventricular tachycardia: a comparison study of children aged 0-4 and 5-9 years. Pacing Clin Electrophysiol 2013; 36:1488.</a></li><li><a class="nounderline abstract_t">Ozaki N, Nakamura Y, Suzuki T, et al. Safety and Efficacy of Radiofrequency Catheter Ablation for Tachyarrhythmia in Children Weighing Less Than 10 kg. Pediatr Cardiol 2018; 39:384.</a></li><li><a class="nounderline abstract_t">Jiang HE, Li XM, Li YH, et al. Efficacy and Safety of Radiofrequency Catheter Ablation of Tachyarrhythmias in 123 Children Under 3 Years of Age. Pacing Clin Electrophysiol 2016; 39:792.</a></li><li><a class="nounderline abstract_t">Kugler JD, Danford DA, Deal BJ, et al. Radiofrequency catheter ablation for tachyarrhythmias in children and adolescents. The Pediatric Electrophysiology Society. N Engl J Med 1994; 330:1481.</a></li><li><a class="nounderline abstract_t">Kugler JD, Danford DA, Houston K, Felix G. Radiofrequency catheter ablation for paroxysmal supraventricular tachycardia in children and adolescents without structural heart disease. Pediatric EP Society, Radiofrequency Catheter Ablation Registry. Am J Cardiol 1997; 80:1438.</a></li><li><a class="nounderline abstract_t">Miyazaki A, Blaufox AD, Fairbrother DL, Saul JP. Cryo-ablation for septal tachycardia substrates in pediatric patients: mid-term results. J Am Coll Cardiol 2005; 45:581.</a></li><li><a class="nounderline abstract_t">LaPage MJ, Saul JP, Reed JH. Long-term outcomes for cryoablation of pediatric patients with atrioventricular nodal reentrant tachycardia. Am J Cardiol 2010; 105:1118.</a></li><li><a class="nounderline abstract_t">Drago F, Placidi S, Righi D, et al. Cryoablation of AVNRT in children and adolescents: early intervention leads to a better outcome. J Cardiovasc Electrophysiol 2014; 25:398.</a></li><li><a class="nounderline abstract_t">Karacan M, Çelik N, Akdeniz C, Tuzcu V. Long-term outcomes following cryoablation of atrioventricular nodal reentrant tachycardia in children. Pacing Clin Electrophysiol 2018; 41:255.</a></li><li><a class="nounderline abstract_t">Gallagher JJ, Svenson RH, Kasell JH, et al. Catheter technique for closed-chest ablation of the atrioventricular conduction system. N Engl J Med 1982; 306:194.</a></li><li><a class="nounderline abstract_t">Huang SK, Graham AR, Lee MA, et al. Comparison of catheter ablation using radiofrequency versus direct current energy: biophysical, electrophysiologic and pathologic observations. J Am Coll Cardiol 1991; 18:1091.</a></li><li><a class="nounderline abstract_t">Van Hare GF, Lesh MD, Scheinman M, Langberg JJ. Percutaneous radiofrequency catheter ablation for supraventricular arrhythmias in children. J Am Coll Cardiol 1991; 17:1613.</a></li><li><a class="nounderline abstract_t">Van Hare GF, Javitz H, Carmelli D, et al. Prospective assessment after pediatric cardiac ablation: demographics, medical profiles, and initial outcomes. J Cardiovasc Electrophysiol 2004; 15:759.</a></li><li><a class="nounderline abstract_t">Backhoff D, Klehs S, Müller MJ, et al. Long-Term Follow-Up After Radiofrequency Catheter Ablation of Accessory Atrioventricular Pathways in Children. JACC Clin Electrophysiol 2018; 4:448.</a></li><li><a class="nounderline abstract_t">Hiippala A, Happonen JM. Population-based single-center outcome for pediatric catheter ablation of common supraventricular tachycardias. Pacing Clin Electrophysiol 2015; 38:115.</a></li><li><a class="nounderline abstract_t">Kubuš P, Vít P, Gebauer RA, et al. Long-term results of paediatric radiofrequency catheter ablation: a population-based study. Europace 2014; 16:1808.</a></li><li><a class="nounderline abstract_t">Dubin AM, Jorgensen NW, Radbill AE, et al. What have we learned in the last 20 years? A comparison of a modern era pediatric and congenital catheter ablation registry to previous pediatric ablation registries. Heart Rhythm 2019; 16:57.</a></li><li><a class="nounderline abstract_t">Kugler JD. Radiofrequency catheter ablation for supraventricular tachycardia. Should it be used in infants and small children? Circulation 1994; 90:639.</a></li><li><a class="nounderline abstract_t">Backhoff D, Klehs S, Müller MJ, et al. Radiofrequency Catheter Ablation of Accessory Atrioventricular Pathways in Infants and Toddlers ≤ 15 kg. Pediatr Cardiol 2016; 37:892.</a></li><li><a class="nounderline abstract_t">Crawford FA Jr, Gillette PC. Surgical treatment of cardiac dysrhythmias in infants and children. Ann Thorac Surg 1994; 58:1262.</a></li><li><a class="nounderline abstract_t">Lazorishinets VV, Glagola MD, Stychinsky AS, et al. Surgical treatment of Wolf-Parkinson-White syndrome during plastic operations in patients with Ebstein's anomaly. Eur J Cardiothorac Surg 2000; 18:487.</a></li><li><a class="nounderline abstract_t">Mavroudis C, Deal BJ, Backer CL, Tsao S. Arrhythmia surgery in patients with and without congenital heart disease. Ann Thorac Surg 2008; 86:857.</a></li><li><a class="nounderline abstract_t">Perry JC, Garson A Jr. Supraventricular tachycardia due to Wolff-Parkinson-White syndrome in children: early disappearance and late recurrence. J Am Coll Cardiol 1990; 16:1215.</a></li><li><a class="nounderline abstract_t">Salerno JC, Garrison MM, Larison C, Seslar SP. Case fatality in children with supraventricular tachycardia in the United States. Pacing Clin Electrophysiol 2011; 34:832.</a></li><li><a class="nounderline abstract_t">Wu MH, Chen HC, Kao FY, Huang SK. Postnatal cumulative incidence of supraventricular tachycardia in a general pediatric population: A national birth cohort database study. Heart Rhythm 2016; 13:2070.</a></li><li><a class="nounderline abstract_t">Cain N, Irving C, Webber S, et al. Natural history of Wolff-Parkinson-White syndrome diagnosed in childhood. Am J Cardiol 2013; 112:961.</a></li></ol></div><div id="topicVersionRevision">Topic 5782 Version 45.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2205383" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Differential diagnosis of supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20956230" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Part 14: pediatric advanced life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26473000" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Part 12: Pediatric Advanced Life Support: 2015 American Heart Association Guidelines Update for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11826634" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Contemporary trends in pediatric sedation and analgesia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4022709" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Guidelines for the elective use of conscious sedation, deep sedation, and general anesthesia in pediatric patients. Committee on Drugs. Section on anesthesiology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8804320" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12586276" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Effectiveness of prehospital synchronous direct-current cardioversion for supraventricular tachyarrhythmias causing unstable hemodynamic states.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27912926" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Acute Management of Refractory and Unstable Pediatric Supraventricular Tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21946177" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Paediatric arrhythmias in the emergency department.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11146016" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Paroxysmal supraventricular tachycardia: outcome after ED care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7420222" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : The ice bag: a new technique for interruption of supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7229788" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Supraventricular tachycardia in children: clinical features, response to treatment, and long-term follow-up in 217 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8059736" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : "Vagal maneuvers" and adenosine for termination of atrioventricular reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2301975" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Supraventricular tachycardia in infants: response to initial treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27974431" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : BET 2: Ice water immersion, other vagal manoeuvres or adenosine for SVT in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341211" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Usefulness of adenosine for arrhythmias in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10937468" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Supraventricular tachycardia in infants, children and adolescents: diagnosis, and pharmacological and interventional therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9568942" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Adenosine in the management of supraventricular tachycardia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10880404" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : July 4, 2000</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023780" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Therapeutic and diagnostic utility of adenosine during tachycardia evaluation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8023780" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Therapeutic and diagnostic utility of adenosine during tachycardia evaluation in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9312997" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Adenosine-induced atrial arrhythmia: a prospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7965442" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Bronchospasm after intravenous administration of adenosine in a patient with asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7639385" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Bronchospasm after intravenous adenosine administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922414" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adenosine and pediatric supraventricular tachycardia in the emergency department: multicenter study and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2306833" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Electrophysiological effects of adenosine in the transplanted human heart. Evidence of supersensitivity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28450351" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Prospective Study of Adenosine on Atrioventricular Nodal Conduction in Pediatric and Young Adult Patients After Heart Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2789912" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9363655" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Role of adenosine in the diagnosis and treatment of tachyarrhythmias in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1944450" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Adenosine and supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1561973" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Supraventricular tachycardia mechanisms and their age distribution in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9427894" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Five-year experience with radiofrequency catheter ablation: implications for management of arrhythmias in pediatric and young adult patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29025197" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Adenosine versus intravenous calcium channel antagonists for supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20194798" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Amiodarone versus procainamide for the acute treatment of recurrent supraventricular tachycardia in pediatric patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8609351" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Pediatric use of intravenous amiodarone: efficacy and safety in critically ill patients from a multicenter protocol.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8074040" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical efficacy and safety of intravenous Amiodarone in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16316969" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Intravenous amiodarone for incessant tachyarrhythmias in children: a randomized, double-blind, antiarrhythmic drug trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25684888" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cardiovascular collapse during amiodarone infusion in a hemodynamically compromised child with refractory supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9265430" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The role of intravenous amiodarone in the management of cardiac arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7753695" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Efficacy and safety of intravenous amiodarone for short-term treatment of paroxysmal supraventricular tachycardia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9770567" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Amiodarone used alone or in combination with propranolol: a very effective therapy for tachyarrhythmias in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3982906" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3797173" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Medicolegal problems in the management of cardiac arrhythmias in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3706928" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Wide complex tachycardia: misdiagnosis and outcome after emergent therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1279580" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Termination of tachycardias by transesophageal electrical pacing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25282062" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Efficacy and safety of high-dose propranolol for the management of infant supraventricular tachyarrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18489621" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Neonatal supraventricular tachycardia: outcomes over a 27-year period at a single institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22903738" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : A multi-institutional analysis of inpatient treatment for supraventricular tachycardia in newborns and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22962431" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554021" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy and risks of medical therapy for supraventricular tachycardia in neonates and infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36576576" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Multicenter cohort study on duration of antiarrhythmic medication for supraventricular tachycardia in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4006125" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Periodic procainamide for paroxysmal tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7355758" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Episodic drug treatment in the management of paroxysmal arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7560629" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1678926" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Use of amiodarone for short-term and adjuvant therapy in young patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11136494" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Amiodarone is safe and highly effective therapy for supraventricular tachycardia in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7897134" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Flecainide and amiodarone: combined therapy for refractory tachyarrhythmias in infancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11823091" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children&lt;1 year of age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29523919" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy and Safety of Low-Dose Amiodarone Therapy for Tachyarrhythmia in Congenital Heart Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30875081" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : A comparison of oral flecainide and amiodarone for the treatment of recurrent supraventricular tachycardia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12189406" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Predictors of refractory tachycardia in infants with supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27033244" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Variation in Antiarrhythmic Management of Infants Hospitalized with Supraventricular Tachycardia: A Multi-Institutional Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28363353" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Propranolol Versus Digoxin in the Neonate for Supraventricular Tachycardia (from the Pediatric Health Information System).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21553267" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : High-dose sotalol is safe and effective in neonates and infants with refractory supraventricular tachyarrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26899545" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : PACES/HRS expert consensus statement on the use of catheter ablation in children and patients with congenital heart disease: Developed in partnership with the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS). Endorsed by the governing bodies of PACES, HRS, the American Academy of Pediatrics (AAP), the American Heart Association (AHA), and the Association for European Pediatric and Congenital Cardiology (AEPC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24033331" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Radiofrequency catheter ablation for supraventricular tachycardia: a comparison study of children aged 0-4 and 5-9 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29119214" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Safety and Efficacy of Radiofrequency Catheter Ablation for Tachyarrhythmia in Children Weighing Less Than 10 kg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27196949" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Efficacy and Safety of Radiofrequency Catheter Ablation of Tachyarrhythmias in 123 Children Under 3 Years of Age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8164700" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Radiofrequency catheter ablation for tachyarrhythmias in children and adolescents. The Pediatric Electrophysiology Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9399718" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Radiofrequency catheter ablation for paroxysmal supraventricular tachycardia in children and adolescents without structural heart disease. Pediatric EP Society, Radiofrequency Catheter Ablation Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15708707" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Cryo-ablation for septal tachycardia substrates in pediatric patients: mid-term results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20381663" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Long-term outcomes for cryoablation of pediatric patients with atrioventricular nodal reentrant tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24303941" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Cryoablation of AVNRT in children and adolescents: early intervention leads to a better outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29318633" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Long-term outcomes following cryoablation of atrioventricular nodal reentrant tachycardia in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7054682" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Catheter technique for closed-chest ablation of the atrioventricular conduction system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1894854" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Comparison of catheter ablation using radiofrequency versus direct current energy: biophysical, electrophysiologic and pathologic observations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2033194" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Percutaneous radiofrequency catheter ablation for supraventricular arrhythmias in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15250858" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Prospective assessment after pediatric cardiac ablation: demographics, medical profiles, and initial outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30067483" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Long-Term Follow-Up After Radiofrequency Catheter Ablation of Accessory Atrioventricular Pathways in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25224363" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Population-based single-center outcome for pediatric catheter ablation of common supraventricular tachycardias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24846163" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Long-term results of paediatric radiofrequency catheter ablation: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30118886" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : What have we learned in the last 20 years? A comparison of a modern era pediatric and congenital catheter ablation registry to previous pediatric ablation registries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8026053" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Radiofrequency catheter ablation for supraventricular tachycardia. Should it be used in infants and small children?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26961570" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Radiofrequency Catheter Ablation of Accessory Atrioventricular Pathways in Infants and Toddlers ≤ 15 kg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7944802" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Surgical treatment of cardiac dysrhythmias in infants and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11024389" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Surgical treatment of Wolf-Parkinson-White syndrome during plastic operations in patients with Ebstein's anomaly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18721574" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Arrhythmia surgery in patients with and without congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2229769" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Supraventricular tachycardia due to Wolff-Parkinson-White syndrome in children: early disappearance and late recurrence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21418251" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Case fatality in children with supraventricular tachycardia in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27287032" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Postnatal cumulative incidence of supraventricular tachycardia in a general pediatric population: A national birth cohort database study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23827401" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Natural history of Wolff-Parkinson-White syndrome diagnosed in childhood.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
